Understanding Patient-Derived Glioblastoma Multiforme Cells’ Proliferation

Glioblastoma multiforme (GBM) is the most common and aggressive type of primary brain tumor. Patients with GBM have a median survival of 15 months. Thus, treating GBM can be achieved by inhibiting the proliferation of the patient-derived cells using leaf extract of B. monnieri.

Summary of Research

Glioblastoma multiforme (GBM) is the most common and aggressive type of primary brain tumor. Patients with GBM have a median survival of 15 months. Current treatments for GBM
are quite limited and research into developing novel therapeutics is warranted. Phytochemical analysis of the plant Bacopa monnieri has revealed high concentrations of terpenoids, a bioactive compound shown to have anti-tumorigenic properties. Considering these properties of terpenoids, it was hypothesized that Bacopa may inhibit GBM cell proliferation in-vitro.

Bacopa crude leaf extract was applied to patient-derived GBM cells & U-87 MG cell line in-vitro. Tested extract concentrations ranged from 4 to 300 μg/mL. After 72 hours of exposure, GBM
cell proliferation was analyzed through a colorimetric WST-1 tetrazolium reduction assay. The results revealed that Bacopa extract inhibited cell proliferation in patient-derived GBM cells
and U-87 MG cell line. The IC50 (50% inhibitory dose) range was between 11 and 33 μg/mL for patient-derived GBM and between 33 and 100 μg/mL for U-87 MG. Data analysis revealed
statistically-significant F-values of 282.8 and 28.9 for the patient-derived GBM and the U-87 MG cells, respectively, with P-values less than 0.001 for both.

In conclusion, Bacopa leaf extract does indeed inhibit the proliferation of patient-derived GBM cells and the U-87 MG cell line, a finding which has never been previously reported or published. With further experimentation, Bacopa has the potential to be used as a novel adjuvant treatment modality, hopefully improving survival rates of GBM-afflicted patients.

Leave a Reply

Understanding Patient-Derived Glioblastoma Multiforme Cells’ Proliferation

Glioblastoma multiforme (GBM) is the most common and aggressive type of primary brain tumor. Patients with GBM have a median survival of 15 months. Thus, treating GBM can be achieved by inhibiting the proliferation of the patient-derived cells using leaf extract of B. monnieri.

Scroll to top

2018 ScienceBuzz Symposium

Click Here to go to the Conference Website

We are excited to announce the first annual ScienceBuzz Symposium, dedicated to middle and high school students. The conference and registration is completely free! Currently, the symposium date is June 9, 2018.

Pre-register for the symposium by visiting the conference website or clicking here. There are a limited number of seats and we expect to fill up quickly, so register ASAP. The event will include several internationally-renowned speakers, workshop sessions, company exhibitions, scholarships, and research presentations. 

 

The 2018 ScienceBuzz Symposium is the first, completely free conference exclusively for middle and high school students. Our theme for this year is “One Day of Powerful Talks.”

It will be hosted in Lehigh Valley, Pennsylvania, but will include students from around the state and nearby regions. The event will have national guest keynote speakers (including a Nobel Prize Laureate, the head of a leading scientific institution, college admissions officers, university professors, leaders in gifted education, and top biopharma executives). It will also include workshop sessions, student poster presentations, five research scholarship awards, organizational and company exhibitions, and unique networking opportunities.

To learn more about the symposium, agenda, and logistical details, visit our website at www.sciencebuzz.wixsite.com/symposium

Support us by contributing to our Kickstarter campaign: